Handelsbanken Fonder
AMLX icon

Handelsbanken Fonder’s Amylyx Pharmaceuticals AMLX Stock Holding History

Handelsbanken Fonder’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,700
Closed -$42K – 1524
2024
Q1 		$42K Buy
14,700
+2,800
+24% +$36.6K ﹤0.01% 1559
2023
Q4 		$175K Buy
+11,900
New +$182K ﹤0.01% 1520
2023
Q1 		– Sell
-6,100
Closed -$225K – 1565
2022
Q4 		$225K Buy
+6,100
New +$216K ﹤0.01% 1385

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Handelsbanken Fonder's AMLX Position: Q2 2024 in Review

Handelsbanken Fonder sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2024, closing a stake of 14,700 shares — an estimated $42K sold.

Handelsbanken Fonder first reported a position in AMLX in Q4 2022 and held it in 3 quarters. The position peaked at $225K in Q4 2022. 119 funds tracked by Wall St. Rank hold AMLX as of Q2 2024.

  • Handelsbanken Fonder reported no remaining Amylyx Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Handelsbanken Fonder sold 14,700 Amylyx Pharmaceuticals shares in Q2 2024, an estimated $42K.
  • Handelsbanken Fonder first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Handelsbanken Fonder's Amylyx Pharmaceuticals position peaked at $225K in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2024.

Based on Handelsbanken Fonder's 13F filing for Q2 2024, filed 5 Aug 2024.